Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers Academic Article uri icon

Overview

MeSH Major

  • Cell Cycle Checkpoints
  • Costimulatory and Inhibitory T-Cell Receptors
  • Immunotherapy
  • Neoplasms
  • T-Lymphocytes
  • Tumor Microenvironment

abstract

  • Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade (ICB). The impact of TMB on outcomes with targeted therapies has not been explored.

publication date

  • February 2019

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC6347551

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-18-1102

PubMed ID

  • 30045933

Additional Document Info

start page

  • 1063

end page

  • 1069

volume

  • 25

number

  • 3